Repligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Repligen Corporation (NASDAQ:RGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $172.83.

RGEN has been the subject of several recent research reports. Barclays began coverage on shares of Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Canaccord Genuity Group reduced their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, JPMorgan Chase & Co. decreased their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded up $0.40 during midday trading on Friday, reaching $127.36. The company's stock had a trading volume of 208,766 shares, compared to its average volume of 729,442. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The stock has a fifty day moving average of $126.70 and a 200 day moving average of $139.91. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52. The firm has a market capitalization of $7.16 billion, a PE ratio of -283.02, a P/E/G ratio of 3.65 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. On average, equities analysts expect that Repligen will post 1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Signaturefd LLC increased its position in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new stake in Repligen in the 4th quarter valued at about $29,000. Raiffeisen Bank International AG purchased a new position in Repligen during the 4th quarter valued at about $29,000. Twin Tree Management LP acquired a new position in Repligen during the first quarter worth about $29,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen in the fourth quarter valued at about $40,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.